安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Study Details | NCT05607550 | Study to Compare Furmonertinib to . . .
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
- FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line . . .
Furmonertinib recently obtained FDA Breakthrough Therapy Designation for the first line treatment of patients with advanced NSCLC with EGFR ex20ins based on the data from the FAVOUR study
- ArriVent Receives FDA Breakthrough Therapy Designation for . . .
The pivotal Phase 3 FURVENT trial (NCT05607550) of furmonertinib for the treatment of first-line NSCLC with EGFR exon 20 insertion mutations is currently enrolling patients globally
- ArriVent’s Topline Pivotal Phase 3 FURVENT Data for . . . - BioSpace
FURVENT is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being conducted jointly with our partner Allist
- Non-Small Cell Lung Cancer (Adenocarcinoma) Clinical Trial . . .
Learn more about clinical trial NCT05607550 and evaluate if this is the right trial for your cancer condition
- FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line . . .
The FURVENT (FURMO-004; NCT05607550) study is a registrational, global, phase 3, randomized, multicenter, open-label study Eligible patients have treatment-naïve, locally advanced or metastatic non-squamous NSCLC with documented EGFR exon 20 insertion mutations and measurable disease per RECIST 1 1
- Arrivent’s Pivotal Phase 3 Furvent Data for Firmonertinib Projected . . .
ArriVent BioPharma anticipates topline data from its global Phase 3 FURVENT trial in early 2026 The trial is evaluating firmonertinib as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations
- P2. 09-18 FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy . . .
The FURVENT (FURMO-004) study is a registrational global, phase 3, randomized, multicenter, open-label study Eligible patients are treatment-naïve, locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations
|
|
|